Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation



Rating:

Share or cite this content

Citations should be made in the following way:
Antoni Torres Marti (Barcelona, Spain). Systemic corticosteroid for treating severe community-acquired pneumonia. International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation

Member's Comments

No comment yet.

Related content which might interest you: Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Severe community-acquired pneumonia Source: Eur Respir Monogr 2016; 74: 101-116 Year: 2016 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Challenges in steroids and anicoagulants in severe COVID-19 pneumonia Source: Virtual Congress 2021 – COVID-19 and acute respiratory failure Year: 2021 is hypercapnia associated with severe forms of community-acquired pneumonia? Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020